End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.

Enrico Franceschi, Raffaele Agati, Alba A. Brandes

Research output: Contribution to journalArticlepeer-review

Abstract

In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological patterns without even affecting the real tumor burden. Moreover, despite the intriguing results in terms of progression-free survival and response rate obtained with these agents, data about survival are superimposable with historical controls. Thus, there is a need for solid end points to evaluate the role of these agents in Phase II trials in the field of neuro-oncology.

Original languageEnglish
Pages (from-to)1713-1717
Number of pages5
JournalExpert Review of Anticancer Therapy
Volume11
Issue number11
Publication statusPublished - Nov 2011

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Fingerprint Dive into the research topics of 'End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.'. Together they form a unique fingerprint.

Cite this